Review
Open access
Sep 2026
The Tumor-Bed Boost Irradiation in Early-Stage Breast Cancer 30 Years After the Landmark Trials: What Is New?
Current evidence supports a more individualized approach to boost prescription based on recurrence risk, patient age, tumor biology, margin status, treatment techniques, and patient preference, and unresolved clinical issues still remain about the management of positive or close margins.
I. Benevento, A. Solazzo, F. Tortoreto et al.
· Journal of Personalized Medi... · 0 citations